US Industry Earnings Intelligence

Diagnostics & Research earnings map

Forward reporting exposure, estimate delivery, earnings growth and company-level event concentration.

Forward window13 Aug to 11 Nov 202613 matched companies

Group read

Delivery and earnings growth are broadly constructive

75% of companies with measured latest results beat estimates, while 100% show positive year-on-year EPS growth. Healthcare carries the largest forward market-cap exposure.

Forward events13next 90 days
Market-cap exposure$366.5Bmatched companies
Latest beat breadth75%latest measured quarter
Positive EPS growth100%year on year

Forward exposure

Diagnostics & Research reporting load by date

Count and matched market cap

Delivery

Latest result breadth

75%beat breadth

Timing

Session certainty

62%estimate coverage

Growth breadth

Positive versus contracting

Company size

Capital at risk by tier

Company attention queue

Most consequential upcoming reports

Ordered by market capitalisation so the largest potential peer and index read-through appears first.

13 shown
TMOThermo Fisher Scientific IncDiagnostics & Research
21 Oct69 days
Event risk15/100Contained
Market cap$169.5BTime unconfirmed
Beat rate100%up to 8 quarters
EPS growth6.0%year on year
Open earnings dossier
DHRDanaher CorporationDiagnostics & Research
20 Oct68 days
Event risk19/100Contained
Market cap$122.5BTime unconfirmed
Beat rate88%up to 8 quarters
EPS growth17.3%year on year
Open earnings dossier
AAgilent Technologies IncDiagnostics & Research
26 Aug13 days
Event risk24/100Contained
Market cap$38.2BAfter the close
Beat rate75%up to 8 quarters
EPS growth21.3%year on year
Open earnings dossier
DGXQuest Diagnostics IncorporatedDiagnostics & Research
20 Oct68 days
Event risk17/100Contained
Market cap$21.6BTime unconfirmed
Beat rate100%up to 8 quarters
EPS growth11.8%year on year
Open earnings dossier
MEDPMedpace Holdings IncDiagnostics & Research
19 Oct67 days
Event risk20/100Contained
Market cap$12.6BTime unconfirmed
Beat rate100%up to 8 quarters
EPS growth17.5%year on year
Open earnings dossier
NEONeoGenomics IncDiagnostics & Research
27 Oct75 days
Event risk38/100Moderate
Market cap$1.4BTime unconfirmed
Beat rate83%up to 8 quarters
EPS growth-year on year
Open earnings dossier
PREPrenetics Global LtdDiagnostics & Research
11 Sep29 days
Event risk44/100Moderate
Market cap$313.5MTime unconfirmed
Beat rate50%up to 8 quarters
EPS growth-year on year
Open earnings dossier
BNRBurning Rock Biotech LtdDiagnostics & Research
14 Sep32 days
Event risk28/100Moderate
Market cap$106.5MTime unconfirmed
Beat rate0%up to 8 quarters
EPS growth-year on year
Open earnings dossier
QUCYQuantum Cyber N.V.Diagnostics & Research
21 Aug8 days
Event risk32/100Moderate
Market cap$67.8MTime unconfirmed
Beat rate100%up to 8 quarters
EPS growth-year on year
Open earnings dossier
PRPOPrecipio IncDiagnostics & Research
17 Aug4 days
Event risk31/100Moderate
Market cap$43.2MAfter the close
Beat rate0%up to 8 quarters
EPS growth-year on year
Open earnings dossier
MDXHMDxHealth SA ADRDiagnostics & Research
13 Aug0 days
Event risk55/100Elevated
Market cap$38.7MAfter the close
Beat rate13%up to 8 quarters
EPS growth-year on year
Open earnings dossier
XWELXWELL Inc.Diagnostics & Research
13 Aug0 days
Event risk40/100Moderate
Market cap$10.6MTime unconfirmed
Beat rate100%up to 8 quarters
EPS growth-year on year
Open earnings dossier
BIAFbioAffinity Technologies, Inc.Diagnostics & Research
13 Aug0 days
Event risk65/100Elevated
Market cap$7.6MTime unconfirmed
Beat rate17%up to 8 quarters
EPS growth-year on year
Open earnings dossier

Forward company tape

Diagnostics & Research upcoming earnings reports

13 shown

Interpretation

How to read group earnings intelligence

Calendar concentration

Counts show operational density. Market-cap exposure identifies dates with greater potential for peer and index read-through.

Delivery breadth

Only the latest measured result per matched company enters the breadth split, preventing long-history companies from dominating.

Growth breadth

Positive year-on-year EPS growth is kept separate from estimate surprise because growth and expectations answer different questions.

Decision use

The page helps prioritise research and event risk. It does not determine whether to buy, sell or expect a directional reaction.

Evidence context